<DOC>
	<DOC>NCT02731469</DOC>
	<brief_summary>BCD-131 is pegylated darbepoetin beta. BCD-131-1 is open clinical trial to evaluate pharmacokinetics, pharmacodynamics, tolerance, safety and immunogenicity of single injection of increasing doses of BCD-131 to healthy volunteers compared to Mircera速 and Aranesp速. Clinical trial will be conducted in two stages. On first stage the optimal dose for therapeutic use of BCD-131 will be determined (subcutaneous injections). On second stage the determined dose will be injected subcutaneously and intravenously.</brief_summary>
	<brief_title>Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Tolerance, Safety and Immunogenicity of Single Injection of Increasing Doses of BCD-131 to Healthy Volunteers Compared to Mircera速 and Aranesp速</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Volunteer are healthy according to screening investigation, including absence of history of hematologic diseases. Results of hematological, biochemical blood analyses are in normal ranges, including serum ferritin, endogenous erythropoietin No history of alcohol or drug abuse. History of using any erythropoiesis stimulating agents. Acute hemorrhage, donation of blood / plasma or blood transfusions during the 2 months prior to study enrollment. History of chronic hemorrhage. History of allergy to any of the excipients of study drug. Current use of drugs or history of diseases that could influence study drug pharmacokinetics. Full list of inclusion and exclusion criteria can be found in Protocol of the study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>